CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Shingles vaccination of adults 50–59 and ≥60 years, U.S.
-
7 2020
-
-
Source: Am J Prev Med. 59(1):21-31
Details:
-
Alternative Title:Am J Prev Med
-
Personal Author:
-
Description:Background:
In 2006, Zoster Vaccine Live (ZVL) was recommended for adults aged ≥60 years. In 2011, ZVL was approved for use, but not recommended, for adults aged 50–59 years.
Purpose:
To assess ZVL coverage among adults aged 50–59 and ≥60 years.
Methods:
Data from the 2013–2017 National Health Interview Surveys (NHIS) were analyzed in 2019 to estimate national ZVL coverage among adults aged ≥50 years. State-specific ZVL coverage among adults aged ≥50 years was assessed using data from the 2017 Behavioral Risk Factor Surveillance System.
Results:
Among adults aged 50–59 years, ZVL coverage was 5.7% in 2017; ranging from 4% to 6% during 2013–2017 (test for trend, p>0.05). ZVL coverage among adults aged 50–59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, 34.9% of adults aged ≥60 years received ZVL, a significant increase from 24.2% in 2013. ZVL coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of ZVL vaccination among adults aged 50–59 and ≥60 years were older age, having 4–9 physician contacts in the past 12 months, and having a usual place for health care.
Conclusions:
This study provides an assessment of ZVL coverage among persons aged ≥50 years before the newly recommended Recombinant Zoster Vaccine (RZV) came into widespread use. Providers should routinely assess adults’ vaccination status, strongly recommend or offer needed vaccines to their patients.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:32389533
-
Pubmed Central ID:PMC9196997
-
Document Type:
-
Funding:
-
Volume:59
-
Issue:1
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-259.72 KB]
